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Abstract
b-blockers and b-agonists are primarily used to treat cardiovascular diseases. Inter-individual variability in response to both
drug classes is well recognized, yet the identity and relative contribution of the genetic players involved are poorly
understood. This work is the first genome-wide association study (GWAS) addressing the values and susceptibility of
cardiovascular-related traits to a selective b1-blocker, Atenolol (ate), and a b-agonist, Isoproterenol (iso). The phenotypic
dataset consisted of 27 highly heritable traits, each measured across 22 inbred mouse strains and four pharmacological
conditions. The genotypic panel comprised 79922 informative SNPs of the mouse HapMap resource. Associations were
mapped by Efficient Mixed Model Association (EMMA), a method that corrects for the population structure and genetic
relatedness of the various strains. A total of 205 separate genome-wide scans were analyzed. The most significant hits
include three candidate loci related to cardiac and body weight, three loci for electrocardiographic (ECG) values, two loci for
the susceptibility of atrial weight index to iso, four loci for the susceptibility of systolic blood pressure (SBP) to perturbations
of the b-adrenergic system, and one locus for the responsiveness of QTc (p,1028). An additional 60 loci were suggestive for
one or the other of the 27 traits, while 46 others were suggestive for one or the other drug effects (p,1026). Most hits
tagged unexpected regions, yet at least two loci for the susceptibility of SBP to b-adrenergic drugs pointed at members of
the hypothalamic-pituitary-thyroid axis. Loci for cardiac-related traits were preferentially enriched in genes expressed in the
heart, while 23% of the testable loci were replicated with datasets of the Mouse Phenome Database (MPD). Altogether these
data and validation tests indicate that the mapped loci are relevant to the traits and responses studied.
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Introduction
The b-adrenergic system controls cardiac contractility and
excitability, heart rate and vascular tone. Atenolol (ate), a selective
b1 receptor antagonist, belongs to the preferred b-blocking
therapies for the management of heart failure, myocardial
infarction, angina and atrial fibrillation, and to the acceptable
first-line therapies for hypertension [1,2]. In contrast, Isoproter-
enol (iso) is a b-agonist that may be administered in cases of
bradycardia, heart block and asthma [3,4]. In experimental
settings, long-term administration of iso to rodents and other
mammals is also used to model left ventricular hypertrophy
(LVH), independently of blood pressure [5]. This is of important
clinical relevance because unless being a consequence of chronic
exercise, LVH is considered as a pathological manifestation in
man. When persisting, this insult may ultimately lead to heart
failure.
Inter-individual variability in response to either drug is well
recognized. In humans, associated clinical concerns pertain to
variance in drug efficacy and occasional adverse side-effects
[6,7,8]. In inbred mice, extensive inter-strain variability of
cardiovascular-related trait values and responsiveness to either
drug was demonstrated earlier [9]. For these latter phenotypes,
heritabilities were typically higher than 0.5 (Table S2), indicating
that a large fraction of the phenotypic variance was under genetic
control.
Until recently, the search for pharmacogenetic determinants
primarily addressed the effects of single genes and variants on drug
disposition and drug response through candidate gene studies. For
ate and iso, the focus was put on genes coding for b-adrenergic
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receptors [10,11,12,13] and members of the downstream signaling
pathways [6,14,15,16,17]. While convincing evidence indicated
that variation within some of these candidates had an impact on
therapy, it was acknowledged that the underlying genetic
architecture involved additional, yet to be found determinants [6].
A more detailed understanding of these determinants and
associated pathways may ultimately lead to new strategies for
better tailored treatment in patients. Our aim was therefore to
provide the scientific community with a set of complementary
biological hypotheses regarding the genetic determinants of the
cardiovascular response to ate and iso. By generating candidate loci
related to a given phenotype in an unbiased manner, genome-wide
association studies (GWAS) offer a powerful tool to address this
goal.
So far, a small number of GWAS have successfully addressed
drug responses or (adverse) effects in humans [18] but none of
them was centered on b-blockers or b-agonists [19]. Specific
difficulties, pertaining to sample size, replication of findings,
phenotype heterogeneity and effect size, make that these
investigations are particularly challenging to implement in humans
[18]. Moreover, controlling for environmental confounders such
as compliance to drug prescription, poly-medication, placebo
effect or diet, to name a few, can be difficult.
To overcome these limitations, our experiments were performed
in a genetic reference population (GRP) of 22 inbred mouse
strains. The benefit of using such a GRP is that because it is
genetically stable and reproducible, it allows data integration
across time and (independent) studies and creates the possibility to
uncover relationships among genes, pathways, and diseases in well
controlled conditions. The phenotypic dataset consisted of the 27
cardiovascular-related traits measured earlier across the various
strains and conditions of treatment [9]. To screen for candidate
loci, we used efficient mixed model association (EMMA) mapping,
a method that corrects for the complex population structure and
genetic relatedness of the inbred strains [20], and applied
conservative adjustment for multiple hypotheses testing.
In a first series of 105 analyses, we searched for associations
between the non-transformed values of the 27 traits and ca 80000
informative SNPs of the mouse HapMap resource [21]. In the
second part of the study, we probed 100 genome-wide scans for
markers associated with pharmacological effects, using approxi-
mated values of trait responsiveness. To substantiate the mapped
loci further, we investigated potential overlaps with independent
functional or genetic evidence obtained in the literature and
various databases of linkage studies, animal mutants and human
GWAS [19,22,23]. We then show that the loci mapped for cardiac
traits are enriched for genes expressed in the heart, while a
significant fraction (23%) of the testable candidates are replicated
in independent cohorts of the MPD [24].
Results
1. GWAS of 27 trait values measured across 22 mouse
strains and four drug conditions
The dataset of 27 phenotypes measured across 22 inbred mouse
strains and four drug conditions was described earlier (Table S1
and [9]). On average, eight to ten biological replicates were
characterized in each strain and treatment condition. To probe for
associations between these values and the informative SNPs of the
mouse HapMap [21], we generated a separate genome-wide
analysis for each trait and treatment condition (ctr, ate, iso1 or iso10
[9]). With the exception of normalized cardiac indices (AWI,
VWI), phenotypes were not adjusted or transformed prior to
searching for associations. In total, 105 EMMA scans were
produced (Figures S1, S2, S3 and S4). Quantile-quantile plots
(QQ-plots) were used to monitor the quality of the GWAS. Hits
were declared nominally significant for p-values #1028 and
suggestive for p-values ranging from 1026 to 1028 (Material and
Methods, Figure S11).
Based on these filters, 50 genome-wide scans produced at least
one suggestive association, 39 had no hit and 16 were excluded
because they demonstrated an inflation of p-values of low to
moderate significance (Figures S1, S2, S3 and S4, Table S3).
Careful examination of the allelic patterns underlying the
significant SNPs, followed by manual imputation of those with
missing alleles, indicated that nine loci were likely candidates, two
of which shared identical strain distribution patterns (SDPs) on
separate chromosomes (Table 1). In addition, 60 other loci were
suggestive for one or the other of the 27 traits (Table S3).
In the paragraphs below, we provide detailed descriptions of the
mapping results for the traits related to body weight (BWS, BWE),
cardiac weight (HW, VW and AW), cardiac indices (VWI and
AWI), systolic blood pressure (SBP), heart rate (HR) and ECG
values. Readers less interested in these details are referred to
Figure 1 for a synoptic view and to Discussion for a general
perspective of these results.
Non-adjusted weight of the heart and cardiac
compartments (HW, VW, AW)
The morphological phenotypes were robust and highly corre-
lated [9]. Of all the EMMA scans obtained with these traits, those
for non-adjusted weight of the cardiac atria (AW) produced the
strongest hits (2log10 p=15.9; Table 1). While no hit passed the
threshold of suggestive significance for non-adjusted HW and VW
(Figures S1, S2, S3 and S4), a small number of additional
candidates were mapped for body weight and cardiac indices.
In the panel A of Figure 2, the four Manhattan plots for AW -
one per treatment condition - are superimposed. Highly significant
hits mapped onto two ca 8 Mb-apart regions of chr 5, called loci 1
and 2 (Table 1, Figure 2). The number of SNPs with low genome-
wide p-values was well above that expected by chance, in
particular for values measured in ctr and ate-treated mice
(Figure 2B).
Locus 1 is a 1.5 Mb segment spanning 18 genes. It is delineated
by nine highly significant and 24 suggestive markers preferentially
associated with AW of ate-treated mice (Table 1). The top positions
were replicated in the ctr and iso1-treated cohorts, albeit at slightly
reduced significance (Figures S1, S2, S3 and S4, Table S3).
Locus 2 encompasses a 1 Mb region tagged by one significant
and one suggestive SNPs associated with AW of ctr mice. Similarly
to locus 1, the top hit was suggestively replicated with AW of ate-
and iso1-treated animals.
Both loci were also significant when considering AW of all mice,
using treatment as a covariate in EMMA (data not shown). They
further overlapped with some of the very few suggestive SNPs
retrieved with body weight (BWS for both loci and BWE for locus
2; Figures S1, S2, S3 and S4, Table S3). In contrast, their
association scores with the other phenotypes, in particular
normalized cardiac indices (AWI and VWI or HWI), were low.
Both intervals include several genes, of which Npffr2 (neuro-
peptide FF receptor 2), Adamts3 (a metalloproteinase of the ECM),
Alb (serum albumin), Afp (a´-feto-protein), Afm (afamin), and
1700007G11Rik carry the most significant hits (Figure 2). Our
microarrays indicated that Cox18 and Ankrd17 were expressed in
mouse cardiac ventricles, while the other transcripts were either
low (Adamts3) or absent (Table S5). Functional studies in animal
models [22] pointed at possible roles in cardiovascular- and/or
growth-related phenotypes for Ankrd17 (locus 1) and Prkg2 (which
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resides ca 0.56 Mb downstream of locus 2). Specifically, Ankrd17-
deficiency led to serious hemorrhages and embryonic lethality in
the mouse [25]. Secondary perturbations included arrest of the
endocardium development, thinner myocardium and poor
trabeculation in the cardiac ventricle. As of Prkg2, several mutant
forms cause mammalian dwarfism [26,27]. Similar functional
approaches seem to exclude Alb, Afp, Fgf5 and Bmp3 from the list of
putative candidates, while mutants of the remaining genes have
not been described [22].
Our results seem to intersect with data obtained by others
(Figure 1). First, the syntenic segments of loci 1 and 2 on rat chr 14
are encompassed by Bw26, a 28 Mb QTL that peaks in the direct
vicinity of Alb (Figure 2) and is associated with hypertrophy of the
left cardiac ventricle, body weight, and systemic arterial diastolic
Figure 1. Synoptic maps of the top loci for cardiovascular-related traits. The genetic maps of twelve loci are presented. Chromosomal
positions are given on the vertical axis (in Mb). Colored boxes are used to differentiate contiguous genes. The ‘‘trait plus treatment’’ combinations
producing the strongest associations are indicated in each plot’s title. The positions of the significant and suggestive hits are indicated by red and
orange arrows, respectively (all hits are detailed in Table S3). Potential overlaps linking these loci with independent evidence obtained from
functional or genetic studies performed in mice, humans and rats are annotated in the respective vertical tracks (see main text for details). For
instance, variants of ADAMTS3 are associated with human height (locus 1). Overlaps with rat QTLs are indicated at the bottom of the maps for loci 1, 2
and 33. DBP: diastolic blood pressure; MI: myocardial infarction; DCM: dilated cardiomyopathy; LVH: left ventricular hypertrophy; CVD: cardiovascular
disease.
doi:10.1371/journal.pone.0041032.g001
Figure 2. GWAS of non-adjusted AW. A. Composite Manhattan plot superimposing the four EMMA scans for non-adjusted AW. Association
scores (-log10 p-value; y-axis) are shown for each chromosomal position (x-axis) tested by EMMA. Suggestive and significant thresholds of association
are indicated by orange and red lines, respectively. B. QQ-plots reporting the -log10 of p-values as obtained by EMMA. The null hypothesis (H0) is
indicated by the dotted line. A strong upper deviation from this line in the region of the lowest p-values is indicative of a true association. C, D. Zoom-
in on loci 1 and 2. Genes are displayed as indicated in the NCBI37/mm9 assembly of the UCSC genome browser [86].
doi:10.1371/journal.pone.0041032.g002
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blood pressure [23,28]. Second, human variants of ADAMTS3
(locus 1) and PRKG2/BMP3 (i.e. immediately downstream of locus
2) are associated with adult height [29,30,31], a particular
haplotype of NPFFR2 (locus 1) confers protection against obesity
in Scandinavians [32] and the syntenic human segment overlap-
ping locus 2 is associated with diastolic blood pressure [33]. The
low scores for cardiac indices and SBP in our analyses suggest that
loci 1 and 2 might be preferentially involved in the control of
organ size and/or weight and/or scaling.
Adjusted weight of the cardiac compartments (VWI, VW/
BWS, AWI, AW/BWS)
We mapped two, respectively seven suggestive loci for
ventricular (VWI and VW/BWS) and atrial (AWI and AW/
BWS) weight indices. These regions did not overlap. As left
ventricular hypertrophy, such as that induced by iso, is a major risk
factor for ventricular dysfunction and heart failure [5], we paid
particular attention to all SNPs associated with cardiac indices.
The most significant region for ventricular indices was tagged
by one intergenic SNP of chr 3 (locus 33, rs31137966; Figure 1 and
Figures S1, S2, S3 and S4, Table S3). This marker mapped on a
0.75 Mb segment located between Plrg1 and Sfrp2. Plrg1 is a
ubiquitous and evolutionarily conserved component of the
spliceosome, while Sfrp2 is an enhancer of procollagen C
proteinase. Both genes may be relevant candidates. First, they
are both expressed in cardiac tissues (Table S5). Second, in the rat,
they belong to Cm67 (CakmC2QTL), a 25 Mb QTL associated with
cardiac index [34]. Third, the human orthologues belong to
segments mapped for left ventricular mass index in a linkage study
of human siblings and for a˜-fibrinogen, a marker of cardiovascular
disease, in a GWAS [35,36]. Fourth, in rodents, Sfrp2 is involved
in fibrosis associated with myocardial infarction [37,38]. And fifth,
in mice, cardio-specific inactivation of Plrg1 induces massive
dilatation and atrophy of both cardiac ventricles characteristic of
severe dilated cardiomyopathy, further leading to post-natal
lethality [39].
Locus 43 was apparently also suggestively associated with the
ventricular indices of iso-treated mice (locus 43, rs6339927 and
rs32349124; Figures S1, S2, S3 and S4, Table S3). Yet, manual
imputation of the underlying markers, followed by score correc-
tion, suggested that this locus was a false positive. Specifically, -
log10 piso1 at rs32838436 was 3.89, while -log10 piso10 at rs33032029
was 2.78.
The strongest signals for atrial indices hit locus 3, a 0.35 Mb
segment of chr 15 defined by four variants of interest (Figure 1).
The top score was retrieved with AW/BWS of iso1-treated mice
(Table 1), while three nearby SNPs were suggestively replicated
across several scans for AWI, AW/BWS and non-adjusted AW
(Figures S1, S2, S3 and S4, Table S3). All four SNPs lacked
genotypic information in one or two of the 22 strains (Table 1). In
the absence of surrogate variants with full allelic information, the
corrected scores could not be imputed. Locus 3 is located in the
proximity of two genes coding for ion transporters, Slc38a2 and
Slc38a4. The product of Slc38a2 is a ubiquitous sodium-dependent
neutral amino acid transporter, called SNAT2 in humans. Given
its high expression level in cardiac tissues (Table S5) and its role in
the regulation of cell volume [40], Slc38a2 might be relevant to the
morphology of cardiac atria.
At least three of the six additional suggestive loci for atrial
indices were of potential interest: loci 20, 59, 63. Locus 20 was
defined by a single variant tagging a 1.8 Mb gene desert between
Slc4a3 and Epha4 on chr 1 (locus 20, rs31792085; Figures S1, S2,
S3 and S4, Table S3). Interestingly, a variant of the syntenic
human segment on chr 2q36.1 is suggestively associated with left
ventricular mass [41]. Moreover, Slc4a3 codes for a Cl2/HCO3
2
anion exchanger that is highly expressed in the heart (Table S5).
While disruption of Slc4a3 alone has no adverse effects on cardiac
performance, functional investigations in mouse mutants suggest
that it is involved in cardiac contractility, b-adrenergic responses
and cardiac Ca2+ handling [42,43].
Locus 59, a 0.16 Mb region defined by three SNPs with
identical SDPs, was associated with atrial indices of ate-treated
individuals (Figures S1, S2, S3 and S4, Table S3). Scores in the
other scans were much reduced, suggesting that the underlying
variants were preferentially associated with b-blockade. These
markers tagged Tbk1 (TANK-binding kinase 1, a signaling
molecule of immune responses and inflammation), Xpot (exportin
t, a t-RNA nuclear exporting factor), and Rassf3 (a member of Ras
effectors and tumor suppressor genes). Microarrays indicated that
both Xpot and Rassf3 were expressed in cardiac tissues (Table S5)
but their potential functions in the heart are not known.
Locus 63, a 45 kb interval defined by four suggestive SNPs
sharing identical SDPs, was associated with the AW/BWS ratio of
ate-treated mice (Figure 1 and Figures S1, S2, S3 and S4, Table
S3). Scores were only slightly reduced in the ctr and iso1-treated
cohorts. Interestingly, the syntenic rat segment on chr 10 is
encompassed by Cm51, a 43 Mb QTL associated with cardiac
mass and hypertension that peaks in close vicinity of these markers
[44]. Tagged genes include Rps6kb1 (ribosomal S6 kinase), Tubd1
(tubulin delta 1), Tmem49 (a trans-membrane protein) and miR21.
All of them are expressed in cardiac tissues and thus might be
relevant for the physiology of cardiac atria. S6 kinase in particular
is a pivotal member of the mTOR/p70(S6K) signaling cascade
that is involved in the regulation of cell size and scaling.
Homozygous disruption of mouse Rps6kb1 does not affect viability
or fertility, but induces a significant decrease of body and organ
growth, especially during embryogenesis [45,46]. Equally inter-
esting, miR-21 is up-regulated in several models mimicking cardiac
hypertrophy, such as neonatal cardiomyocytes treated with iso [47]
or mice subjected to trans-aortic banding [48,49,50]. Functional
investigations further suggest that miR-21 contributes to myocar-
dial disease by activating molecular mechanisms of cardiac fibrosis
[51,52].
Body weight (BWS and BWE)
Five loci were suggestively associated with body weight, of
which at least four tagged seemingly relevant candidate regions
and/or overlapped hits mapped for related traits. In addition to
the two suggestive regions mentioned above (see chapter on scans
for non-adjusted AW), an intergenic SNP of chr 1 located ca
0.6 Mb downstream of Sec16b was suggestively associated with
BWE of iso-treated animals (locus 24, rs32046817; Figure 1 and
Figures S1, S2, S3 and S4, Table S3). This region appeared just
below threshold in the remaining analyses (ctr, ate) and was
suggestive when considering BWE of all mice, using treatment as a
covariate (data not shown). Interestingly, human variants of and
around SEC16B have been repeatedly associated with body mass
index and obesity [53,54].
Another intergenic marker, located between Luzp1 and Htr1d on
chr 4, was suggestively associated with BWE of iso10-treated mice
(locus 42, rs32851583; Figure 1 and Figures S1, S2, S3 and S4,
Table S3). Genome-wide significance was only slightly reduced in
the remaining analyses (ctr, ate, iso1). Polymorphisms around
human HTR1D (serotonin receptor 1D) are associated with adult
height [30] and, suggestively, appetite control and anorexia [55],
which may all be relevant to BW.
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Body weight gain (BWE/BWS)
Significant associations for body weight gain were specifically
identified using trait values of iso10-treated mice, mapping on a ca
7.5 Mb segment of chr 2 (locus7, Table 1). Closer inspection of the
underlying SDPs indicated that the most significant scores were
slightly inflated. Moreover, these genotypes shared SDPs compat-
ible with those of suggestive locus 32 on chr 3 (Table S3), which
complicates data interpretation. The mechanisms behind differ-
ential body weight gain upon iso10 stimulation are not known.
Locus 7 contains more than 100 genes, while locus 32 best tags
Fstl5 (follistatin-like 5) and Golim4 (a membrane protein of the
Golgi).
Systolic blood pressure (SBP)
The identification of genetic variants affecting human blood
pressure and hypertension has been particularly challenging
[33,56,57] and our results are in line with this trend. Thus, a
single signal passed the suggestive filter for SBP (locus 17, Table 1).
This hit consisted in an isolated intergenic SNP on chr 1, with
associations at nearby markers well below thresholds. Evidence
supporting a possible link between this region and blood pressure,
whether from human GWAS, mutant mice, other animal models
or functional studies, is currently lacking. Yet, as summarized in
Table 2 and discussed below, this hit was replicated with the
independent values of the Sugiyama1 cohort of the MPD [24,58].
Heart rate in conscious mice (HR)
Inspection of the Manhattan and QQ-plots for HR (TC)
indicated that either no hit passed the suggestive threshold (ctr and
iso1) or the EMMA scans were inflated with p-values of low to
moderate significance (ate and iso10; Figures S1, S2, S3 and S4). A
candidate region that might survive correction for inflation was
defined by a single significant SNP located immediately upstream
of Zfp563 on chr 17 (chr 17, rs33155499; Table 1). This hit was the
strongest with the values of ate-treated mice but markedly less
significant in ctr condition or under b-adrenergic stimulation.
Zfp563 encodes a transcription factor of unknown function. Yet, in
the rat, Zfp563 is encompassed within Hrtrt10, a 27 Mb QTL
associated with HR of females placed under low-salt diet and
volume depletion with furosemide [59].
ECG traits
A small number of candidate loci were obtained with ECG trait
values, in particular QRS interval and QTc (Table 1). Significant
associations were also mapped for Qamp and Ramp (Figures S1,
S2, S3 and S4, Table S3). Yet, since amplitudes and areas of ECG
waves are composite parameters of little clinical use, these data are
not discussed further. For the other traits, the scores did not go
beyond suggestive significance (Figures S1, S2, S3 and S4, Table
S3).
Four significant and two suggestive hits of chr 6 were specifically
associated with QRS interval of ctr mice (locus 9, Figure 1 and
Table 1). The underlying 0.5 Mb candidate segment tagged Sox5,
a transcription factor involved in embryonic development and
chondrogenesis [60]. Functional evidence linking Sox5 with
cardiac electrical activity is lacking but variation in human SOX5
is associated with PR interval [61] and resting HR [62]. Our
results might be in line with these data, even though the scores for
PR or HR were low in this region (Figures S1, S2, S3 and S4,
Table S3).
Two isolated intergenic SNPs were significantly associated with
QTc (loci 10 and 11, Table 1). The strongest one, located in a
gene desert of chr 14, was specific of QTc of ate-treated mice. The
second SNP hit an independent intergenic segment between Rragc
and Pou3f1 on chr 4 and was specific of QTc measured under iso10
stimulation (Figure 1). The same position was suggestive in the
scan of non-corrected QT values. Independent evidence support-
ing a possible relationship between these hits and ECG values,
whether from human GWAs, mutant mice, other animal models
or functional studies is lacking but microarrays detected Rragc
expression in cardiac tissue.
2. GWAS of drug effects
With the exception of BW, all phenotypes were measured in
separate animals for each drug treatment. Thus the values of the
pharmacological effects of ate or iso on a particular trait were not
available per individual mouse. Since EMMA works best when
using trait values of several (typically five to ten) replicates per
strain but has less power to analyze strain means [20], we scanned
for variants underlying trait responsiveness using inferred individ-
ual values of ate- and iso10-mediated effects. These values were
generated by computing, for each trait and treated mouse, the
difference or the fold change between the value measured in that
individual and the average value measured in the ctr mice of the
matching strain. The effects of iso10 vs ate were computed following
a similar scheme.
Altogether, 100 genome-wide scans were analyzed for the
pharmacological effects (Figures S5, S6, S7 and S8): 42 produced
no hit above suggestive significance and 25 were rejected upon
inspections of the QQ-plots and/or phenotypic variances (Mate-
rial and Methods). The remaining 33 experiments pointed at 11
significant and 46 suggestive loci associated with trait responsive-
ness (Table 2, Table S4). A selection of the most significant results
is presented below. These results are described in the paragraphs
below, while a summary is presented in Figure 3.
Responsiveness of traits related to cardiac indices and
body weight
Three significant loci, all specifically associated with the
responsiveness of cardiac atria to iso10, were identified (loci
AE1, AE2, AE8, Table 2). For the effects on the other traits, in
particular VWI, only a small number of suggestive hits were
obtained (Figures S5, S6, S7 and S8, Table S4).
Locus AE1 consisted in a single SNP of slightly inflated
significance on chr 1 (Table 2). The primary variant tagged Dst, a
gene coding for a giant cytoskeletal protein called dystonin. A
member of the family of plakin proteins, dystonin is capable of
crosslinking the major filament systems in contractile cells.
Alternatively spliced and tissue-specific isoforms are expressed in
mammalian epithelia, neurons and skeletal muscle [63,64]. In the
heart, Dst expression is high (Table S5), the major muscle isoform
localizing at the Z-disc, H-zone, sarcolemma and intercalated discs
[65]. In mice, dystonin deficiency is associated with dystonia
musculorum, an inherited sensory neuropathy that often leads to
pre-weaning death [66]. In some models, these symptoms are
accompanied by increased expression of cardiac stress markers
similar to those induced by prolonged stimulation with iso, in
particular NppA, Myh7 and Serca2a [5,65]. However, it is not
known whether b-adrenergic stimulation is capable of regulating
Dst or whether similar pathways affect the physiology of cardiac
atria.
Locus AE2 tagged Ntng1 on chr 3 (Table 2). This 1.2 Mb region
was delineated by eight SNPs sharing an identical SDP. Ntng1
codes for netrin G1, a non-essential protein involved in axon
guidance during nervous system development in vertebrates
[22,67]. In adult tissues, Ntng1 is essentially expressed in the
brain, with little to no expression in the heart, as confirmed in the
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microarrays (Table S5). Variants of human NTNG1 have been
suggestively associated with anorexia [55], while the orthologous
rat gene is encompassed within four QTLs for cardiac mass and
several others for body and organ weight [23]. Possible
relationships between Ntng1 and trait responses to pharmacological
treatments have not been documented.
Locus AE8 spans a ca 1.7 Mb intergenic segment between Kcnj2
and Sox9 on chr 11 (Table 2). Based on their respective functions
in the heart, both genes appear as attractive candidates. Kcnj2
codes for Kir2.1, an inwardly rectifying potassium channel
expressed in tissues such as skeletal muscle and heart, while Sox9
codes for a transcription factor involved in chondrogenesis and
cardiac valve development [22,68]. Homozygous disruption of
Kcnj2 demonstrated that Kir2.1 was essential for IK1, a cardiac
current involved in the maintenance of the negative resting
potential and excitability of cardiac myocytes [69]. Associated
phenotypes included bradycardia and alterations of the waveform
of action potentials and the firing rate of myocytes [69]. In
cultured cardiac myocytes, IK1 is inhibited by iso [70,71]. Co-
immunoprecipitation assays further showed that Kir2.1, b1-
adrenergic receptors and at least two other proteins were
organized in a macromolecular complex in cardiac myocytes
[70]. Further interesting, familial mutations of human KCNJ2 are
linked with atrial fibrillation, long QT syndrome and short QT
syndrome, while nearby variants on chr 17 are associated with QT
interval [72].
Responsiveness of systolic blood pressure
Six loci were significantly associated with the responsiveness of
SBP to perturbations of the b-adrenergic system. These regions
were all identified when analyzing the fold changes between values
measured under stimulation with iso10 and those recorded under
ate (Table 2). Loci AE7 and AE9 were each supported by single
markers with inflated p-values (Table 2). Of the remaining four
segments, loci AE6 and AE11 were tagged by markers with
identical SDPs, suggesting that one or the other locus might be a
false positive.
Notwithstanding these considerations, at least two loci specif-
ically pointed at genes belonging to the same functional pathway:
locus AE6 for Trhde on chr 10 and locus AE10 for Trhr on chr 15.
Locus AE6 spans 1.8 Mb, with all underlying markers residing
within introns of Trhde. Locus AE10 covers eight genes within a
1.2 Mb segment; two of the underlying variants are located in
introns of Trhr, while the remaining 25 SNPs are intergenic
(Figures S5, S6, S7 and S8, Table S4). Of the seven, respectively
eight strains carrying the minor allele at each locus, five are
identical, indicating that both regions are in partial but not
complete linkage disequilibrium (data not shown). Mice with the
minor alleles tended to exhibit distinct blood pressure values
between the ate and iso10 treatments, while the differences were
more marginal in the other strains (Figure S10 and [9]).
Trhr codes for the thyrotropin-releasing hormone (Trh) recep-
tor, while Trhde codes for the Trh-degrading enzyme. Trh
represents the most proximal member of the hypothalamic-
pituitary-thyroid axis. It is primarily synthesized in the hypothal-
amus but is also produced in other areas of the brain and in non-
neuronal tissues such as the gastrointestinal tract, the heart and
reproductive organs. Trh functions as a tripeptide hormone that
maintains thyroid hormone homeostasis via regulation of thyroid-
stimulating hormone production and secretion. It further controls
the release of other hormones, such as prolactin, growth hormone,
vasopressin, and insulin. Trh exerts direct roles in cardiovascular
physiology in general, and on blood pressure in particular [73].
Thus, administration of Trh to rats triggers dose-dependent
increase of SBP, HR and cardiac contractility [74,75]. The
preoptic area (POA) of the brain, a region crucial for the central
regulation of arterial blood pressure, is one of the non-
hypothalamic areas that produces Trh [73]. In spontaneously
hypertensive rats (SHR), the Trh content of the POA is
approximately doubled when compared to normotensive controls.
Also, injection of antisense Trh oligonucleotide in SHRs decreased
Trh levels and normalized SBP [76], establishing Trh of the POA
as a key regulator of blood pressure. Trh is also produced locally in
the heart, primarily by fibroblasts [75], although in our case,
transcript levels detected in cardiac ventricles were low (Table S5).
Interestingly, stimulation of cultured cardiac fibroblasts with iso
enhances Trh expression [75], indicating that Trh is able to
respond to b-adrenergic activation.
At this stage, it is well conceivable that genetic variation of Trhr
and Trhde modulates the action of Trh on SBP. In humans, a case-
control study of 120 hypertensives and 63 normotensives indeed
suggested that polymorphisms of the TRHR promoter were
associated with essential hypertension [77]. Yet, the mechanisms
that link pharmacological perturbations of the b-adrenergic system
with the Trh pathway remain to be established.
3. Validation tests
To substantiate the relevance of the mapped loci further, we
explored two complementary strategies. First, we tested whether
loci for cardiac traits were enriched in genes expressed in the
heart. Second, we searched for replication of the hits mapped by
EMMA, using independent datasets of the MPD.
Cardiac transcriptomics
Cardiac transcript levels were measured in untreated ventricles
of C57BL/6J and KK/HlJ hearts by microarrays. Our working
hypothesis was that the loci associated with cardiac traits
contained more genes expressed in the heart than the rest of the
genome. To test for this, we considered the 587 genes located
within 500 kb of the SNPs suggestive for cardiac-related traits (i.e.
cardiac geometry and indices, HR and ECG values), that were
probed by the arrays. 354 (60%) of these genes were expressed in
the heart. This percentage was significantly higher than the
fraction (55%) of all genes expressed in the same samples
(p=0.004, binomial test), indicating that the candidate loci were
enriched for genes expressed in cardiac tissues.
Replication in independent cohorts
The MPD provides a repository of phenotypic traits measured
in numerous mouse cohorts [24] that can be used to probe for
replication of association hits. For each phenotype with suggestive
hits and testable replication cohorts, a dataset was selected within
the MPD, with the restriction that it included a minimum of 19
strains with documented mouse HapMap genotypes. When
multiple such datasets were available, the one with the closest
age match and largest number of strains was chosen. Each dataset
selected was submitted to the EMMA server [21], excluding values
measured in females and/or in wild-derived strains. It was then
checked whether the primary hits passed the 5% significance
Figure 3. Synoptic maps of the top loci associated with the effects of iso and ate. The genetic maps of eight loci are presented and
annotated as described in the legend of Figure 1. CHF: congestive heart failure; AF: atrial fibrillation; LQTS: long QT syndrome.
doi:10.1371/journal.pone.0041032.g003
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threshold in the replication study (with corrected inflated/deflated
p-values). Of the 35 testable loci, eight (23%) were replicated at
least once (Table 3). A binomial test showed that this fraction
represented a significant enrichment (p=0.0003), as only 5%
replication would have been expected by chance.
Six of the replicated loci relate to body weight and cardiac
indices (Table 3), which further reflects the marked robustness of
these traits. Even though the number of testable datasets was more
limited for the remaining traits, two other loci could be replicated.
The first one consisted in the single marker mapped for SBP (locus
17), which was replicated with the values of Sugiyama1 (Table 3).
This variant was immediately adjacent to another two markers,
rs31667929 and rs31572758, that both reached genome-wide
significance in the replication analysis but were absent from our set
of informative SNPs (data not shown). The other replicated region
was locus 16, which was defined by a single marker suggestively
associated with the non-corrected QT intervals of ctr mice (Table
S3). This SNP was located within Khdrbs2, a gene coding for an
RNA-binding protein of poorly understood function.
Discussion
The most significant hits identified in this study consist in three
candidate loci related to cardiac and body weight, three loci for
electrocardiographic (ECG) parameters, two loci for the suscep-
tibility of atrial weight index to iso, four loci for the susceptibility of
SBP to perturbations of the b-adrenergic system, and one locus for
the responsiveness of QTc. An additional 60 loci were suggestive
for one or the other phenotype, while 46 were suggestive for one or
the other effect of the treatments. Apart from the many apparent
correlations with data extracted from the literature and other
databases, we are confident that the mapped loci are reliable
candidates for two other reasons: first, the hits suggestively
associated with cardiac-related traits tagged genomic regions
preferentially enriched in genes expressed in the heart (p=0.004);
second, a significant fraction (23%; p=0.0003) of the testable
candidate markers was replicated with independent publicly-
available datasets. To discuss these results further, the following
points need to be considered.
One of the major challenges of association studies in general
and of in silico mapping in particular is to discern true from false
positives without losing (too many) false negatives. By using trait
values of eight to ten biological replicates for each phenotype as
well as applying a stringent filter to control for missing alleles,
conservative thresholds to control for multiple hypotheses testing,
and EMMA to correct for population structure and genetic
relatedness of the mouse strains, we greatly reduced the number of
spurious positive associations. Quality controls, in particular QQ-
plots and careful inspections of the patterns of allelic distributions
at the top hits further restricted the number of likely false positives.
A significant fraction of the loci identified for the 27 phenotypes
was not specific of trait values measured under a single drug
treatment but often overlapped across several if not all scans
produced for the given trait. This was concordant with our
previous observation that robust phenotypes (i.e. those relating to
body and to a lesser extent cardiac weight) were marginally
affected by ate and iso [9]. In contrast, most of the loci for ECG
values were significant only with respect to a specific drug
treatment.
Since the phenotypes were measured in separate cohorts for
each drug treatment, individual values of the pharmacological
effects of ate or iso were not available but had to be inferred. This
said, it is important to emphasize that measuring pharmacological
effects in hundreds of individuals may not be easily implementable
for invasive phenotypes such as heart weight. One may argue that
the approximations are adding experimental noise to the mapped
loci, potentially increasing the number of false positives. However,
we note that the vast majority of the hits associated with the effects
of iso10 vs ate treatments (i.e. those for which the values of trait
variance were often the largest) were also retrieved when analyzing
the reverse ate vs iso10 combinations. Had the computed values
been noisy, then these results would have been difficult to
replicate. Notwithstanding these limitations, our design produced
an attractive list of candidate genes. The identification of at least
two members of the hypothalamic-pituitary-thyroid axis as
Table 3. Replication studies.
Trait RD (MPD) RD Trait RD ID
RD strains
in EMMA
Strains in
common Loci, this study Loci, replicated
BWS Lightfoot 1 BW 7553 36 22 2 L1, L2 2 L1, L2
BWE Tordoff 3 BW 7564 31 21 4 L2, L22, L24, L42 3 L22, L24, L42
AW Reed 1 HW 7580 24 17 4 L1, L2, L3, L68 2 L1, L2
AWI Reed 1 %HW/BW 7582 24 17 5 L3, L28, L59, L61, L71 0
AW/BWS Reed 1 %HW/BW 7582 24 17 3 L3, L20, L63 0
VWI Reed 1 %HW/BW 7582 24 17 1 L43 0
VW/BWS Reed 1 %HW/BW 7582 24 17 2 L33, L43 1 L33
SBP Sugiyama 1 SBP 7205 19 14 1 L17 1 L17
PR Xing 1 PR 7588 26 16 3 L18, L54, L65 0
QRS Xing 1 QRS 7589 26 16 2 L9, L45 0
QT Xing 1 QT 7590 26 16 8 L10, L15, L16, L21, L30, L60, L62,
L67
1 L16
ST Xing 1 ST 7591 26 16 9 L16, L19, L40, L52, L57, L62, L64,
L67, L69
0
For each trait listed, the suggestive hits mapped by EMMA were tested using the indicated replication dataset (RD) of the MPD. RD ID: MPD ID number of the trait
considered for the replication test; RD strains in EMMA: number of strains of the RD used in EMMA; strains in common: number of strains in common between this study
and the RD.
doi:10.1371/journal.pone.0041032.t003
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putative modulators of the responsiveness of SBP to perturbations
of the b-adrenergic system appears particularly relevant. Indeed it
seems rather unlikely that such a result would emerge by pure
chance. As mentioned in the corresponding chapter, the under-
lying markers seem to discriminate between ‘‘SBP-responsive’’ and
‘‘SBP non-responsive’’ strains for the considered ate and iso10
treatments. However, we reported earlier that most of the 22
mouse lines reacted to a ten-fold lower dose of iso (i.e. iso1) by
reducing SBP [9]. Therefore, none of these strains can be
considered as a general non-responder. Additional investigations
will be required to dissect the underlying mechanisms further.
Unlike other b-blockers, ate undergoes little or no metabolism in
the liver and is primarily eliminated unchanged by the kidneys
[78,79]. In contrast, iso is metabolized within minutes into inactive
metabolites by the liver catechol-O-methyltransferase (COMT)
[80]. Since the 22 strains carry a single, identical Comt haplotype,
the pharmacokinetics of both ate and iso is expected to be only
marginally influenced by genetic variation of metabolizing
enzymes. This seems well supported by the absence of genes
involved in drug metabolism in our list of candidates. Along
similar lines, we note that the 22 strains carry the same Adrb1
haplotype, Adrb1 coding for the main subtype of b-adrenergic
receptors in the heart.
On the principle, it is well acknowledged that computational
association mapping in inbred mice provides high-resolution
mapping. However, the power of this strategy greatly depends on
the size and genetic diversity (recombination) of the chosen strains,
the complexity of the trait studied, and the frequency of the
underlying variants [20,21,81]. A panel such as our GRP is well
suited to detect loci of strong genetic effects for traits of moderate
complexity but has little power to uncover variants with small
effect size. This is well illustrated by the relatively modest number
of hits identified, that rarely exceeded a single putative locus in any
genome-wide scan. Our attempts at analyzing modular pheno-
types, that combined multiple traits and/or treatment conditions,
did not improve this general outcome (data not shown). Thus, not
only the measured traits but also the effects of the drugs are likely
governed by a complex architecture of genetic variants. Our
results also fit with the notion that the whole strategy is well
designed to map common variants, with MAFs of the top markers
typically ranging from 0.3 to 0.5.
High-resolution mapping of the mouse phylogeny recently
established that the genomes of classical inbred lines were
overwhelmingly of Mus musculus domesticus origin, with limited
contributions from Mus musculus musculus and Mus musculus castaneus
subspecies [82,83]. In the present set of strains, this translates into
genomes being on average of 94.5% M. m. domesticus origin, while
the remaining fraction is composed of an estimated 5.2% M. m.
musculus and 0.3% M. m. castaneus haplotypes, respectively. There is
also a strong bias toward multiple lines sharing the same M. m.
musculus haplotype in some regions [82]. Reduced genetic diversity
precludes the identification of the majority of the genetic
determinants existing in natural populations and likely accounts
for a large part to the moderate number of loci identified.
Conversely, it may further explain the apparent large portion of
the phenotypic variance explained by our candidate loci, even for
otherwise naturally complex traits.
At this stage, it would be unreasonable to expect that the
identified loci are the causal variants and thus should be confirmed
by genotyping. Indeed, the mouse HapMap (ca 80¢000 SNPs)
does not contain all of the genetic variation between the strains,
which, according to the latest figures, amounts to ca 4 mio SNPs
per classical inbred genome [83]. Because linkage disequilibrium
(LD) regions in these mice span in the range of a megabase or
more [21,83], it is likely that hundreds of linked variants exist in
any implicated region. For similar reasons, discussing the identity
of putative candidate genes in more details than what is provided
with the results would be too premature and clearly speculative.
Even in inbred mice, mutations naturally occur at a certain rate.
For the reasons mentioned above, we did not perform confirma-
tory genotyping and thus cannot formally exclude that one or the
other marker mapped in the phenotyped animals differs from that
reported in the HapMap database. While chances that such events
would precisely affect the reported candidates are low, we also
reasoned that the amount of genetic differences between a
phenotyped animal and the genotyped animal of the same strain
is anyway several orders of magnitude smaller than the genetic
differences between the strains. Moreover, since many of the
reported loci are supported by more than a single SNP, it seems
unlikely that multiple mutation events (or genotyping errors) would
simultaneously affect multiple consecutive variants in any given
strain. For these reasons, we believe that natural mutation events
have little impact on our general conclusions.
In summary, we have three complementary pieces of evidence
in favor of the correctness of our results: first, looking at external
data overlapping with our studies, we generally observed
consistent behavior. Second, among the candidate genes associ-
ated with the cardiac-related traits, there is a significant
enrichment for genes expressed in the heart. Third, we have
accumulated a number of associations pointing to genes that have
previously been implicated in cardiac functioning or whose
molecular function makes such a role very plausible. Nevertheless,
it is important to emphasize that further independent studies will
be needed to replicate and refine the loci we identified, to map the
underlying causative genes and variants, and to functionally
validate them. Future experiments may include more comprehen-
sive expression profiling across the strains and treatments, as well
as properly designed replication studies. To improve statistical
power and mapping resolution, one may also consider comple-
menting the panel of inbred strains with well-chosen informative
lines such as those of the Hybrid Mouse Diversity Panel [81], the
Collaborative Cross [84] or wild-derived strains [82].
Knowing which genes are involved in drug response is a key
step to understand the biology of the measured traits and
associated diseases. Translating these findings into humans can
potentially provide valuable insights into the nature of the genes
and pathways that modulate inter-individual response variability
to therapies with b-blockers or b-agonists. A more detailed
understanding of these determinants and their relationships will
ultimately lead to new or improved strategies for personalized
treatment in patients suffering from cardiovascular disorders.
Materials and Methods
Ethics Statement
All animal procedures described previously [9] had been approved
by the "Service de la consommation et des affaires ve´te´rinaires du
canton de Vaud" (authorization nu 1649; http://www.vd.ch/fr/
autorites/departements/dse/consommation-et-affaires-veterinaires/)
and were performed in accordance with the National Institutes of
Health (NIH) guidelines for the care and use of laboratory animals.
Phenotypes
The details of the phenotypic dataset were described previously
[9]. The measured trait values are also available through the
Mouse Phenome Database [24], a web portal that provides access
to a large collection of datasets and online tools to visualize and
investigate mouse phenotypes. To generate the individual values of
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trait responsiveness to ate and iso, we computed for each trait and
treated mouse (ate, iso10), the difference (for Qamp, QRSarea,
Samp) or the fold change (FC; all other phenotypes) between the
value measured in that individual and the average value measured
in the ctr mice of the matching strain.
EMMA
EMMA scans [20] were produced using non-transformed trait
values and 79922 informative SNPs of the mouse HapMap
resource [21]. Strain C3H/HeOuJ was excluded from the original
dataset due to low genetic coverage. SNPs were declared
informative if allele information was known in at least 20 of the
22 strains and a minimum of four strains carried the minor allele
at the specified position. SNPs with lower minor allele frequencies
(MAFs) and/or missing genotypes were indeed likely to generate
spurious associations, in particular since, for rare variants,
identical SDPs could often be attributed to more than one
chromosomal location.
For each phenotype, four EMMA scans were generated, each
one using trait values measured in a single treatment condition (ctr,
ate, iso1 and iso10). An exception pertains to the analysis of BWS
for which a single scan integrated the values of all mice.
The significance of the associations was evaluated with an F-test
(REMLt) and conservative thresholds of significance were set using
the Bonferroni correction for multiple hypotheses testing. The
distributions of the obtained versus expected genome-wide p-values
were assessed by QQ-plots. Hits were declared nominally
significant for p-values#1028 and suggestive for p-values ranging
from 1026 to 1028. The former corresponds to a strict Bonferroni
threshold, as -log10(0.05/(47999*89)) = 7.9, where 47999 is the
number of SDPs covered by the 79922 informative SNPs and 89 is
the number of GWAS that passed QQ-plot inspection. Since such
a stringent correction is likely to miss many true positives, we also
reported the results at an intermediate significance range. Its
upper bound of 1026 was motivated by estimating the number of
truly independent tests. To this end we used the number of
eigenvectors required to explain 99.5% of the variation of the data
[85], which turned out to be 16 for our phenotypes. In order to
estimate the number of independent genotypes we ran EMMA on
the permuted phenotypes and looking at the smallest p-value
(median p-value across the permutations = 4.91461024), we
inferred the number of independent tests per phenotype to be its
inverse (i.e. 2035). The effective total number of tests is thus equal
to 1662035, while the corresponding threshold is -log10(0.05/
(1662035)) = 5.8.
Whenever possible, the associations obtained as significant at
positions with incomplete SDPs were manually imputed and
corrected, using information of a compatible nearby variant with a
fully known allele set.
The percentage of phenotypic variance explained at each locus
was calculated with EMMA. Approximated values of the effects of
the treatments on 25 of the 27 traits were analyzed using the same
settings and filters, with the added condition that for each strain s,
measured phenotype pm and approximated phenotype pa,
SD pm,sð Þ

SD pa,sð Þv3. Differences were analyzed as non-trans-
formed values, while FCs were log-transformed prior to running
EMMA.
Microarrays
The 30 to 40% most apical fractions of the cardiac ventricles
were excised from C57BL/6J and KK/HlJ mouse hearts
(n = 4 per strain), snap-frozen in liquid nitrogen, and stored at
270uC. Tissues were homogenized with a Tissue Lyzer system in
the presence of metal beads (Qiagen). Total RNA was extracted
using the mirVana isolation kit of Ambion. RNA quality was
confirmed on a Bioanalyzer system (Agilent Technologies). Poly-
A+ RNA purification, cDNA libraries preparation, labeling and
hybridization onto Affymetrix Mouse Gene 1.0 ST arrays, as well
as washing and scanning of the arrays were performed at the
Lausanne Genomics Technologies Facility (LGTF) following
standard protocols. Each sample was analyzed on a separate
array. All arrays passed standard quality controls. Statistical
analyses were performed using the statistical language R (http://
www.R-project.org) and the Limma Bioconductor package
(http://www.Bioconductor.org). Log2 normalized expression sig-
nals were calculated from Affymetrix CEL files using the RMA
algorithm.
To compute the set of expressed genes, the mixture of two
Gaussian functions was fitted to the log expression values, which
was bimodal (Figure S9). The first component, peaking at around
2, fitted the non-expressed genes, whereas the second component,
peaking at around 6.5, fitted the expressed genes. Expressed genes
are those which belong to the second component with at least 95%
confidence, i.e., genes that have a log expression value higher than
3.55.
Supporting Information
Figure S1 Manhattan and QQ-plots for 27 traits mea-
sured in ctrmice. QQ-plot-based quality control is indicated as
‘‘passed’’ or ‘‘failed’’.
(PDF)
Figure S2 Manhattan and QQ-plots for 26 traits mea-
sured in ate-treated mice. QQ-plot-based quality control is
indicated as ‘‘passed’’ or ‘‘failed’’.
(PDF)
Figure S3 Manhattan and QQ-plots for 26 traits mea-
sured in iso1-treated mice. QQ-plot-based quality control is
indicated as ‘‘passed’’ or ‘‘failed’’.
(PDF)
Figure S4 Manhattan and QQ-plots for 26 traits mea-
sured in iso10-treated mice. QQ-plot-based quality control is
indicated as ‘‘passed’’ or ‘‘failed’’.
(PDF)
Figure S5 Manhattan and QQ-plots for the effects of
iso10 treatment on 25 traits. QQ-plot-based quality control is
indicated as ‘‘passed’’ or failed’’. Phenotypes for which any of the
differences between an individual trait value and its matching
mean strain value exceeded 3 SD are labelled as ‘‘var test failed’’.
(PDF)
Figure S6 Manhattan and QQ-plots for the effects of ate
treatment on 25 traits. QQ-plot-based quality control is
indicated as ‘‘passed’’ or failed’’. Phenotypes for which any of the
differences between an individual trait value and its matching
mean strain value exceeded 3 SD are labelled as ‘‘var test failed’’.
(PDF)
Figure S7 Manhattan and QQ-plots for the effects of
iso10 vs ate treatments on 25 traits. QQ-plot-based quality
control is indicated as ‘‘passed’’ or failed’’. Phenotypes for which
any of the differences between an individual trait value and its
matching mean strain value exceeded 3 SD are labelled as ‘‘var
test failed’’.
(PDF)
Figure S8 Manhattan and QQ-plots for the effects of ate
vs iso10 treatments on 25 traits. QQ-plot-based quality
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control is indicated as ‘‘passed’’ or failed’’. Phenotypes for which
any of the differences between an individual trait value and its
matching mean strain value exceeded 3 SD are labelled as ‘‘var
test failed’’.
(PDF)
Figure S9 Distribution of cardiac mRNA expression
levels as measured by microarrays. The mixture of two
Gaussian functions was fitted to the log expression values. The first
component, peaking at around 2, fits the non-expressed genes,
whereas the second component, peaking at around 6.5, fits the
expressed genes. Non-expressed genes are those which belong to
the first component with at least 95% confidence, i.e., those genes
that have a log expression value less than 2.33 (red line).
(PDF)
Figure S10 Boxplots showing the SBP values of 22
strains treated with ate (in red) and iso10 (in blue).
Strains are segregated according to their genotype at marker
rs29354390 in Trhrde (locus AE6).
(PDF)
Figure S11 Analysis flowchart. This flowchart summarizes
the analysis of the 27 phenotypes measured across the 22 inbred
strains. Details referring to the boxes shaded in grey have been
published previously [9]. These phenotypes are also freely
available through the Mouse Phenome Database (project
Maurer1; http://phenome.jax.org/). Analyses of the drug re-
sponses were performed following a similar scheme, except that
the values were not physically measured in individual mice but
approximated, as detailed in the main text.
(PDF)
Table S1 Phenotypes and abbreviations used in this
study.
(XLS)
Table S2 Heritabilities (h2) for 27 traits and trait
responsiveness to ate and iso, as computed by EMMA.
The values of the genetic variance components for the various
traits and responses were computed by fitting EMMA without any
SNP but just using the kinship matrix [20]. On average, the
heritabilities for the effects of iso10 or iso10 vs ate were ca 10 to15%
lower than those of the measured traits, indicating that a
significant fraction of trait responsiveness to these treatments was
genetically determined. In contrast, the values for the effects of ate
were lower (typically h2,0.5), consistent with our previous
observation that the phenotypic changes induced by b-blockade
were moderate for most phenotypes [9]. NA: not applicable; ND:
not done.
(XLS)
Table S3 Suggestive and significant hits mapped for the
27 traits. For each SNP, the association scores are given as the
negative logarithm of the p-values calculated in EMMA, across the
105 genome-wide scans (columns K to DK). The data are ranked
by position, from chr 1 to chr 17 (rows 5 to 391).
(XLS)
Table S4 Suggestive and significant hits mapped for the
effects of the treatments. For each SNP, the association scores
are given as the negative logarithm of the p-values calculated in
EMMA across 201 genome-wide scans (columns L to HD). The
data are ranked by position, from chr 1 to chr 19 (rows 4 to 217).
(XLS)
Table S5 Log2 normalized cardiac expression values of
the main candidate genes. Transcripts were measured by
microarrays in the cardiac ventricles of untreated C57BL/6J and
KK/HlJ mice (n = 4 per strain). Values were calculated from
Affymetrix CEL files using the RMA algorithm. Data are listed by
probeset and are ranked by locus.
(XLS)
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